Stockscreener 앱 받기
2.15
4.44%
-0.10
시간 외 거래:
2.20
0.05
+2.33%
전일 마감가:
$2.25
열려 있는:
$2.28
하루 거래량:
5.57M
Relative Volume:
2.41
시가총액:
$250.60M
수익:
$6.65M
순이익/손실:
$-136.32M
주가수익비율:
-1.8733
EPS:
-1.1477
순현금흐름:
$-112.04M
1주 성능:
+13.76%
1개월 성능:
+61.65%
6개월 성능:
+95.45%
1년 성능:
+85.34%
1일 변동 폭
$2.09
$2.31
1주일 범위
$1.785
$2.315
52주 변동 폭
$0.91
$2.465
Fate Therapeutics Inc Stock (FATE) Company Profile
명칭
Fate Therapeutics Inc
전화
858.875.1803
주소
12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA
Compare FATE vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
FATE
Fate Therapeutics Inc
|
2.15 | 262.26M | 6.65M | -136.32M | -112.04M | -1.1477 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Fate Therapeutics Inc Stock (FATE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-31 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2025-10-27 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2024-11-18 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2024-06-17 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2023-03-27 | 재개 | Wells Fargo | Equal Weight |
| 2023-01-24 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2023-01-06 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-06 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2023-01-06 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2023-01-06 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2023-01-06 | 다운그레이드 | Stifel | Buy → Hold |
| 2023-01-06 | 다운그레이드 | Truist | Buy → Hold |
| 2023-01-06 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2023-01-03 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2022-12-22 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2022-12-15 | 개시 | Goldman | Sell |
| 2022-11-04 | 재개 | Cantor Fitzgerald | Overweight |
| 2022-10-10 | 개시 | Canaccord Genuity | Buy |
| 2022-08-18 | 재개 | Wells Fargo | Overweight |
| 2022-07-28 | 개시 | Needham | Hold |
| 2022-07-11 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2022-06-03 | 개시 | Robert W. Baird | Neutral |
| 2022-02-11 | 재개 | BMO Capital Markets | Market Perform |
| 2021-12-15 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2021-12-07 | 개시 | Cowen | Outperform |
| 2021-11-09 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-08-26 | 개시 | Morgan Stanley | Equal-Weight |
| 2021-06-07 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2021-05-07 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2021-04-26 | 재개 | Jefferies | Buy |
| 2021-02-26 | 개시 | BofA Securities | Buy |
| 2021-02-26 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2021-02-11 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2021-01-27 | 재개 | H.C. Wainwright | Neutral |
| 2020-05-13 | 개시 | H.C. Wainwright | Buy |
| 2020-03-04 | 개시 | Barclays | Overweight |
| 2020-01-09 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2019-12-30 | 재확인 | Mizuho | Buy |
| 2019-12-09 | 업그레이드 | Wells Fargo | Market Perform → Outperform |
| 2019-11-12 | 개시 | SunTrust | Buy |
| 2019-11-06 | 다운그레이드 | Wells Fargo | Outperform → Market Perform |
| 2019-10-01 | 개시 | Stifel | Buy |
| 2019-08-09 | 개시 | BTIG Research | Buy |
| 2019-07-22 | 개시 | Cantor Fitzgerald | Overweight |
| 2019-07-12 | 개시 | Oppenheimer | Outperform |
| 2019-06-13 | 개시 | Mizuho | Buy |
| 2019-06-07 | 개시 | ROTH Capital | Neutral |
| 2019-05-31 | 개시 | Guggenheim | Buy |
| 2019-05-24 | 재개 | Citigroup | Buy |
| 2019-03-28 | 개시 | SVB Leerink | Outperform |
| 2019-01-03 | 다운그레이드 | Stephens | Overweight → Equal-Weight |
| 2018-11-05 | 개시 | Jefferies | Buy |
| 2018-08-01 | 개시 | Citigroup | Buy |
| 2018-03-06 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
모두보기
Fate Therapeutics Inc 주식(FATE)의 최신 뉴스
BofA Securities Maintains Fate Therapeutics(FATE.US) With Hold Rating, Raises Target Price to $2.2 - Moomoo
FATE Stock Price, Quote & Chart | FATE THERAPEUTICS INC (NASDAQ:FATE) - ChartMill
Fate therapeutics CEO Bahram Valamehr sells $54,482 in shares - Investing.com UK
Fate therapeutics CEO Bahram Valamehr sells $54,482 in shares By Investing.com - Investing.com Australia
Fate Therapeutics (FATE) officer sells 25,590 shares in tax-related transaction - Stock Titan
Fate Therapeutics (FATE) CEO executes 28,946-share sell-to-cover tax sale - Stock Titan
Fate Therapeutics to present CAR T-cell therapy data at medical conferences - StreetInsider
Fate Therapeutics to present CAR T-cell data at medical conferences - Investing.com
Off-the-shelf CAR T trials in cancer and autoimmune at 2026 ASCO, EULAR - Stock Titan
Jefferies initiates Fate Therapeutics stock with buy rating on autoimmune potential - Investing.com India
[144] FATE THERAPEUTICS INC SEC Filing - Stock Titan
Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets - TradingView
Jefferies initiates Fate Therapeutics stock with buy rating on autoimmune potential By Investing.com - Investing.com South Africa
Jefferies Initiates Fate Therapeutics(FATE.US) With Buy Rating, Announces Target Price $4 - Moomoo
Solid Tumor Treatment Race Heats Up as Multi-Billion-Dollar Oncology Market Enters High-Growth Phase - ChartMill
Needham Maintains Fate Therapeutics(FATE.US) With Hold Rating, Announces Target Price $2.25 - Moomoo
Fate Therapeutics Releases Q1 2026 Financial Results - AlphaStreet
Fate Therapeutics, Inc. 2026 Q1 10-Q Report: Financials, Risk Factors, and Key Disclosures - Minichart
Fate Therapeutics earnings beat by $0.02, revenue topped estimates - Investing.com Canada
FT819 Remodels Lupus B Cells in Clinical Trial - CRISPR Medicine News
Fate Therapeutics Reports Q1 2026 Financial Results, Advances FT819 and FT839 CAR T-Cell Trials with Extended Cash Runway into 2028 - Minichart
Fate Therapeutics (FATE) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Fate Therapeutics (NASDAQ: FATE) narrows Q1 2026 loss as R&D costs fall - Stock Titan
Fate Therapeutics 1Q 2026: Revenue $1.3M, EPS $(0.26) — 10-Q Summary - TradingView
Fate Therapeutics Reports First Quarter 2026 Financial Results and Business Updates - The Manila Times
Fate Therapeutics Q1 operating loss narrows, cash runway extended into 2028 - TradingView
Fate Therapeutics: Q1 Earnings Snapshot - KTVB
Fate Therapeutics reports Q1 2026 net loss $31.2M, cash and investments $174.8M; runway into 2028 - TradingView
Fate Therapeutics (NASDAQ: FATE) trims Q1 loss, extends cash runway and advances FT819 - Stock Titan
Fate: 'Hold' FT819 Regimen B Dosing And Potential FDA Alignment In H2 2026 (NASDAQ:FATE) - Seeking Alpha
FATE SEC FilingsFate Therapeutic 10-K, 10-Q, 8-K Forms - Stock Titan
Fate Therapeutics presents CAR T-cell therapy data at ASGCT - Investing.com UK
Fate Therapeutics presents CAR T-cell therapy data at ASGCT By Investing.com - Investing.com South Africa
Fate Therapeutics Showcases FT819 Clinical Activity in SLE - GlobeNewswire
Fate Therapeutics (FATE) Eps Diluted (TTM) - Zacks Investment Research
Number of shareholders of Fate Therapeutics, Inc. – NASDAQ:FATE - TradingView
MSN Money - MSN
FATE Technical Analysis | Trend, Signals & Chart Patterns | FATE THERAPEUTICS INC (NASDAQ:FATE) - ChartMill
Fate Therapeutics Inc (FATE) Stock Price Today & Analysis - Gotrade
Fate Therapeutics (FATE) officer exercises 166,664 options, holds 609k shares - Stock Titan
Fate Therapeutics Inc (FATE) News, Articles, Events & Latest Updates - Stocktwits
Director at Fate Therapeutics (NASDAQ: FATE) exercises 25,000 stock options - Stock Titan
FATE Therapeutics (NASDAQ: FATE) director exercises options, boosts direct stake - Stock Titan
Piper Sandler Maintains Fate Therapeutics(FATE.US) With Buy Rating, Maintains Target Price $6 - Moomoo
HC Wainwright Issues Positive Estimate for FATE Earnings - MarketBeat
H.C. Wainwright Maintains Fate Therapeutics(FATE.US) With Buy Rating, Maintains Target Price $7 - Moomoo
FDA selects Fate Therapeutics’ FT819 for manufacturing pilot program By Investing.com - Investing.com India
Fate Therapeutics (FATE) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat
FDA selects Fate Therapeutics’ FT819 for manufacturing pilot program - Investing.com
Fate Therapeutics selected for U.S. FDA chemistry, manufacturing, and controls development and readiness pilot program to support manufacturing readiness of FT819 - marketscreener.com
Fate Therapeutics Selected for U.S. FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program to Support Manufacturing Readiness of FT819 - The Manila Times
Fate Therapeutics Inc (FATE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.98%
0.12%
자본화:
|
볼륨(24시간):